GenFleet Tightens Remuneration Committee Mandate to Bolster Governance

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has issued an announcement.

GenFleet Therapeutics has updated the terms of reference for its Board Remuneration Committee, setting out a more detailed framework for managing pay and performance evaluation for directors and senior management. The revised document clarifies the committee’s composition, requiring a majority of independent non-executive directors, and specifies that its chair must be an independent board member.

The updated mandate significantly expands the committee’s responsibilities, from designing remuneration schemes and appraisal standards to reviewing compensation for appointments, termination and misconduct. It also reinforces safeguards on conflicts of interest, ensures no director participates in setting their own pay, and aligns share-based incentives and pay structures with Hong Kong Listing Rules, supporting greater transparency and stronger corporate governance for stakeholders.

More about Genfleet Therapeutics (Shanghai), Inc. Class H

GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative therapeutic products. Listed in Hong Kong, it operates under the regulatory framework of the Hong Kong Stock Exchange and is governed by a board structure that includes specialized committees for oversight and governance.

The company’s operations rely on a structured system of director and senior management oversight, where remuneration and performance incentives are aligned with corporate objectives and industry benchmarks. Its governance practices are shaped by Chinese corporate law, Hong Kong listing requirements, and its own Articles of Association to support transparent and compliant management.

Average Trading Volume: 1,619,374

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$10.31B

Learn more about 2595 stock on TipRanks’ Stock Analysis page.